313 related articles for article (PubMed ID: 30999110)
1. Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials.
Sorich MJ; Rowland A; Karapetis CS; Hopkins AM
J Thorac Oncol; 2019 Aug; 14(8):1440-1446. PubMed ID: 30999110
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported outcomes as a prognostic marker of survival in patients with advanced nonsmall cell lung cancer treated with immunotherapy.
Hopkins AM; Wagner J; Kichenadasse G; Modi N; Rowland A; Sorich MJ
Int J Cancer; 2020 Dec; 147(11):3085-3089. PubMed ID: 32492185
[TBL] [Abstract][Full Text] [Related]
3. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial.
Hopkins AM; Kichenadasse G; Abuhelwa AY; McKinnon RA; Rowland A; Sorich MJ
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33803256
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment lung immune prognostic index as a biomarker in advanced non-small-cell lung cancer patients receiving first line pembrolizumab.
Veccia A; Sforza V; Vattemi E; Inno A; Kinspergher S; Dipasquale M; Gori S; Morabito A; Baldi I; Caffo O
Immunotherapy; 2021 Sep; 13(13):1093-1103. PubMed ID: 34190578
[TBL] [Abstract][Full Text] [Related]
5. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
Mezquita L; Auclin E; Ferrara R; Charrier M; Remon J; Planchard D; Ponce S; Ares LP; Leroy L; Audigier-Valette C; Felip E; Zerón-Medina J; Garrido P; Brosseau S; Zalcman G; Mazieres J; Caramela C; Lahmar J; Adam J; Chaput N; Soria JC; Besse B
JAMA Oncol; 2018 Mar; 4(3):351-357. PubMed ID: 29327044
[TBL] [Abstract][Full Text] [Related]
6. Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab.
Hopkins AM; Kichenadasse G; Garrett-Mayer E; Karapetis CS; Rowland A; Sorich MJ
Clin Cancer Res; 2020 Jul; 26(13):3280-3286. PubMed ID: 32086341
[TBL] [Abstract][Full Text] [Related]
7. Prognosis stratification of cancer patients treated with immune checkpoint inhibitors through lung immune prognostic index: a meta-analysis and systematic review.
Guo Y; Pan Y; Wan J; Gong B; Li Y; Kan X; Zheng C
BMC Cancer; 2024 Apr; 24(1):523. PubMed ID: 38664760
[TBL] [Abstract][Full Text] [Related]
8. Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
Riudavets M; Auclin E; Mosteiro M; Dempsey N; Majem M; Prelaj A; López-Castro R; Bosch-Barrera J; Pilotto S; Escalera E; Tagliamento M; Mosquera J; Zalcman G; Aboubakar Nana F; Ponce S; Albarrán-Artahona V; Dal Maso A; Spotti M; Mielgo X; Mussat E; Reyes R; Benítez JC; Lupinacci L; Duchemann B; De Giglio A; Blaquier JB; Audigier-Valette C; Scheffler M; Nadal E; Lopes G; Signorelli D; Garcia-Campelo R; Menis J; Bluthgen V; Campayo M; Recondo G; Besse B; Mezquita L; Planchard D
Clin Lung Cancer; 2024 May; 25(3):233-243.e8. PubMed ID: 38105153
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer.
Wang W; Huang Z; Yu Z; Zhuang W; Zheng W; Cai Z; Shi L; Yu X; Lou G; Hong W; Zhang Y; Chen M; Song Z
Front Oncol; 2020; 10():572853. PubMed ID: 33163403
[TBL] [Abstract][Full Text] [Related]
10. Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab.
Hopkins AM; Kichenadasse G; Karapetis CS; Rowland A; Sorich MJ
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503948
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma.
Parent P; Auclin E; Patrikidou A; Mezquita L; Martínez Chanzá N; Dumont C; Rodriguez-Vida A; Llacer C; Lozano R; Ratta R; Merseburger AS; Sternberg CN; Baciarello G; Colomba E; Fuerea A; Besse B; Loriot Y; Lavaud P
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831409
[TBL] [Abstract][Full Text] [Related]
12. Association of the pretreatment lung immune prognostic index with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors.
Hou B; Wang P; Liu T; Chen S; Li T; Zhang S; Tao H; Li X; Hu Y
Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101748. PubMed ID: 34182184
[TBL] [Abstract][Full Text] [Related]
13. Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma.
Carril-Ajuria L; Lavaud P; Dalban C; Negrier S; Gravis G; Motzer RJ; Chevreau C; Tannir NM; Oudard S; McDermott DF; Laguerre B; Hammers HJ; Barthelemy P; Plimack ER; Borchiellini D; Gross-Goupil M; Jiang R; Lee CW; de Silva H; Rini BI; Escudier B; Albigès L
Eur J Cancer; 2024 Jun; 204():114048. PubMed ID: 38653033
[TBL] [Abstract][Full Text] [Related]
14. Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab.
Passiglia F; Galvano A; Rizzo S; Incorvaia L; Listì A; Bazan V; Russo A
Int J Cancer; 2018 Mar; 142(6):1277-1284. PubMed ID: 29080213
[TBL] [Abstract][Full Text] [Related]
15. Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index.
Ortega-Franco A; Hodgson C; Raja H; Carter M; Lindsay C; Hughes S; Cove-Smith L; Taylor P; Summers Y; Blackhall F; Califano R
Target Oncol; 2022 Jul; 17(4):453-465. PubMed ID: 35781861
[TBL] [Abstract][Full Text] [Related]
16. Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.
Kichenadasse G; Miners JO; Mangoni AA; Rowland A; Hopkins AM; Sorich MJ
JAMA Oncol; 2020 Apr; 6(4):512-518. PubMed ID: 31876896
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment Lung Immune Prognostic Index Is a Prognostic Marker of Chemotherapy and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
Minami S; Ihara S; Komuta K
World J Oncol; 2019 Feb; 10(1):35-45. PubMed ID: 30834050
[TBL] [Abstract][Full Text] [Related]
18. Association of the pretreatment lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced hepatocellular carcinoma.
Sun T; Guo Y; Sun B; Chen L; Ren Y; Zhu L; Zhang L; Liu Y; Zheng C
Eur J Med Res; 2023 Jul; 28(1):225. PubMed ID: 37408056
[TBL] [Abstract][Full Text] [Related]
19. The Lung Immune Prognostic Index May Predict the Efficacy of Different Treatments in Patients with Advanced NSCLC: A Meta-Analysis.
Xie J; Zang Y; Liu M; Peng L; Zhang H
Oncol Res Treat; 2021; 44(4):164-175. PubMed ID: 33657566
[TBL] [Abstract][Full Text] [Related]
20. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Fehrenbacher L; Spira A; Ballinger M; Kowanetz M; Vansteenkiste J; Mazieres J; Park K; Smith D; Artal-Cortes A; Lewanski C; Braiteh F; Waterkamp D; He P; Zou W; Chen DS; Yi J; Sandler A; Rittmeyer A;
Lancet; 2016 Apr; 387(10030):1837-46. PubMed ID: 26970723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]